Accessibility Menu
H-cyte logo

H-cyte(OTC) HCYT

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year+100%
1 Month+100%
N/A
H-cyte last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-26
H-cyte stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+100%USD 0.002026-08-19
1 month+100%USD 0.002026-07-21
3 month-42.86%USD 0.002026-05-06
Year to date-42.86%USD 0.002025-12-31
1 year+100%USD 0.002025-08-25
3 year-99.92%USD 0.502023-08-25
5 year-100%USD 36.902021-08-27
Since inception-100%USD 350.002019-01-09

H-cyte Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$453.00K

Net Income (TTM)

-$9.09M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 10, 2023

HCYT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About H-cyte

H-CYTE, Inc. is a biopharmaceutical firm based in the United States, focused on developing treatments for chronic respiratory and pulmonary diseases. The company specializes in autologous cellular therapy solutions and has a product supply agreement with Rion, LLC to combat chronic obstructive pulmonary disease (COPD).

Products and Services
  • Autologous cellular therapy solutions for chronic lung conditions
  • Biologic compound for chronic obstructive pulmonary disease (COPD)
  • Research and development in innovative respiratory treatments
Growth Outlook
  • Potential market expansion in chronic respiratory disease treatments
  • Strategic partnerships may enhance product distribution
  • Focus on innovative therapies aligns with industry trends
Financial Highlights
  • Q3 2023 net income of -$496,000, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Cash and cash equivalents of $543,882 as of Q3 2023, supporting operational needs
H-CYTE, Inc. operates in a niche market with significant growth potential, particularly in the treatment of chronic respiratory diseases. The company's focus on innovative therapies positions it well within the biotechnology sector. Despite recent financial challenges, including a net loss in Q3 2023, the firm maintains a strategic approach to product development and partnerships. The current cash reserves provide a foundation for continued operations and research efforts. Investors may find H-CYTE's commitment to addressing unmet medical needs in respiratory health compelling as the company navigates its growth trajectory.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Michael W. Yurkowsky

Website

www.hcyte.com

Headquarters

Tampa, FL 33607, US

HCYT Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$608.00K

Operating Income

-$4.33M

EBITDA

-$4.82M

Operating Cash Flow

-$1.39M

Capital Expenditure

$0.00

Free Cash Flow

-$1.39M

Cash & ST Invst.

$543.88K

Total Debt

$4.44M

H-cyte Performance Analysis

H-cyte annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,611,518N/A
20222022-12-31USD 453,460-71.9%
H-cyte sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30-100.0%
Q42022-12-31N/A
Q12023-03-31100.0%
Q32023-09-30N/A
H-cyte annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -32.93N/A
20222022-12-31USD -35.066.5%
H-cyte sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-3052.9%
Q42022-12-3118.4%
Q12023-03-3125.1%
Q32023-09-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$106.00K

-342.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

-$496.00K

+88.9%

EBITDA

-$421.00K

+47.3%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$543.88K

+1085.5%

Total Debt

$4.44M

-20.4%

Accounts Receivable

$15.83K

-60.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$4.44M

+14.7%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$361.99K

+59.1%

Operating Cash Flow

-$361.99K

+59.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCNTPoint of Care Nano-Technology, Inc.
$0.01-90.00%
ALSEAlseres Pharmaceuticals, Inc.
$0.01+100.00%
MSITFMedical Services International Inc.
$0.00+0.00%
CNBIChina BCT Pharmacy Group, Inc.
$0.00+100.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About HCYT

What is the current price of H-cyte?

H-cyte is trading at N/A per share.

What is the 52-week range for H-cyte?

Over the past 52 weeks, H-cyte has traded between N/A and N/A.

How much debt does H-cyte have?

As of the most recent reporting period, H-cyte reported total debt of $3.92M.

How much cash does H-cyte have on hand?

H-cyte reported $0.00 in cash and cash equivalents in its most recent financial results.

What is H-cyte’s dividend yield?

H-cyte does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services